Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NanoViricides Inc (NNVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: NNVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6.5
1 Year Target Price $6.5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -62.12% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.30M USD | Price to earnings Ratio - | 1Y Target Price 6.5 |
Price to earnings Ratio - | 1Y Target Price 6.5 | ||
Volume (30-day avg) 1 | Beta 1.15 | 52 Weeks Range 0.94 - 1.92 | Updated Date 09/15/2025 |
52 Weeks Range 0.94 - 1.92 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.69 |
Earnings Date
Report Date 2025-09-03 | When - | Estimate -0.2 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -57.38% | Return on Equity (TTM) -99.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 17834509 | Price to Sales(TTM) - |
Enterprise Value 17834509 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.11 | Shares Outstanding 16072000 | Shares Floating 15504658 |
Shares Outstanding 16072000 | Shares Floating 15504658 | ||
Percent Insiders 3.53 | Percent Institutions 8.31 |
Upturn AI SWOT
NanoViricides Inc
Company Overview
History and Background
NanoViricides Inc. was founded in 2003. It is a development-stage company focused on developing drugs for the treatment of viral diseases using its nanoviricide technology. The company has focused on multiple viral diseases, including influenza, herpes, and coronaviruses.
Core Business Areas
- Drug Development: Development of antiviral drugs based on the nanoviricide platform technology.
- Preclinical Research: Conducting preclinical studies and research to evaluate the safety and efficacy of nanoviricide drug candidates.
- Intellectual Property: Securing and maintaining intellectual property rights related to its nanoviricide technology and drug candidates.
Leadership and Structure
Dr. Anil Diwan serves as the President and Executive Chairman. The company has a scientific advisory board and a management team focused on research and development.
Top Products and Market Share
Key Offerings
- NV-HHV-101 (Herpes Cure): A preclinical drug candidate being developed as a potential cure for herpes simplex virus (HSV) infections. NanoViricides does not currently have revenue generating products on the market. Main competitors include pharmaceutical giants like GlaxoSmithKline (GSK) and Merck (MRK) who have established products for the treatment, but not cure, of herpes.
- NV-CoV-2 (COVID-19): A preclinical drug candidate being developed as a potential treatment for COVID-19. NanoViricides does not currently have revenue generating products on the market. Competitors include Pfizer (PFE), Moderna (MRNA), and Regeneron (REGN) who have established and approved treatments.
Market Dynamics
Industry Overview
The antiviral drug market is a significant and growing market due to the ongoing threat of viral infections. Innovation in antiviral therapies is driven by the need to combat emerging and drug-resistant viruses.
Positioning
NanoViricides is positioned as a nanotechnology-based antiviral drug developer, aiming to provide broad-spectrum antiviral solutions that target the virus structure itself. Its competitive advantage lies in its potentially novel mechanism of action.
Total Addressable Market (TAM)
The global antiviral drugs market is expected to reach hundreds of billions of USD in the coming years. NanoViricides is positioned to capture a portion of this TAM through successful drug development and commercialization; however, they are still in the preclinical stage.
Upturn SWOT Analysis
Strengths
- Novel Nanoviricide Technology
- Broad Spectrum Antiviral Potential
- Targeting Difficult-to-Treat Viruses
- Strong intellectual property portfolio
Weaknesses
- Preclinical Stage of Development
- Lack of Revenue-Generating Products
- Limited Financial Resources
- High Regulatory Risk
Opportunities
- Partnerships with Pharmaceutical Companies
- Government Funding and Grants
- Expansion into New Viral Disease Targets
- Advancements in Nanotechnology
Threats
- Competition from Established Pharmaceutical Companies
- Clinical Trial Failures
- Regulatory Hurdles
- Technological Advancements by Competitors
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- GSK
- MRK
- JNJ
- ABBV
Competitive Landscape
NanoViricides faces intense competition from established pharmaceutical companies with significantly more resources and approved products. NanoViricides' advantage lies in its novel technology, but it faces significant challenges in proving its efficacy and safety and successfully navigating the regulatory process.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily reflected in research and development activities and intellectual property portfolio expansion, rather than revenue generation.
Future Projections: Future growth depends on the successful development and commercialization of its nanoviricide drug candidates. Analyst estimates are highly speculative given the early stage of development.
Recent Initiatives: Recent initiatives include advancing preclinical studies for COVID-19 and herpes treatments, and securing additional patents for its technology.
Summary
NanoViricides is a high-risk, high-reward development-stage company with a novel nanoviricide technology. The company's strengths lie in its broad-spectrum antiviral potential and strong intellectual property. However, it faces significant challenges due to its preclinical stage, limited financial resources, and competition from established pharmaceutical giants. The company needs to secure partnerships and funding to advance its drug candidates and successfully navigate the regulatory landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry News and Publications
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. Investing in NanoViricides Inc. involves significant risks, including the risk of loss of investment.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NanoViricides Inc
Exchange NYSE MKT | Headquaters Shelton, CT, United States | ||
IPO Launch date 2005-10-26 | Executive Chairman, President, CEO & Secretary Dr. Anil R. Diwan Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 7 | Website https://www.nanoviricides.com |
Full time employees 7 | Website https://www.nanoviricides.com | ||
NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections comprising NV-CoV-2 Oral Syrup and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form, which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric treatments. It also offers NV-387 Solution for injection, infusion, and inhalation to treat severe cases that are not hospitalized and carried out by an injection; and injectable solution that delivered directly into the lungs as a fog created using portable battery operated nebulizer devices, which enables action at infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company develops NV-HHV-1, a skin cream for the treatment of Shingles rash, which has completed non-clinical pharmacology studies; oral drug with NV-HHV-1 as the active ingredient for the treatment of HSV-1 cold sores and HSV-2 genital ulcers; and other drug candidates in HIVCide program for the treatment of Dengue and Ebola virus, as well as provides Nanoviricide platform technology to treat various types of viruses. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.